KIMS Q1 FY27 net profit drops 47% to ₹41.5 crore despite 35% revenue surge
Synopsis
KIMS grew revenue by 35% and added nearly 1,000 beds in a year — yet net profit nearly halved. The paradox is deliberate: rapid network expansion is compressing margins in the short term, and the real question is how fast newer hospitals, including the freshly launched Palakkad unit, can ramp up to justify the ₹1,500 crore QIP war chest.
Key Takeaways
KIMS reported a 47.2 per cent YoY drop in consolidated net profit to ₹41.5 crore in Q1 FY27 , down from ₹78.6 crore in Q1 FY26.
Revenue from operations rose 35.3 per cent to ₹1,179.5 crore , driven by higher patient volumes and network expansion.
EBITDA grew 16 per cent YoY to ₹223.4 crore , but EBITDA margin narrowed to 18.9 per cent from 22.1 per cent .
Total bed capacity increased to 7,459 as of 30 June 2026 , up from 5,499 a year earlier — a near 36 per cent rise.
A new hospital was launched in Palakkad, Kerala in Q1 FY27; some units have performed complex procedures including lung transplants.
Remaining proceeds from the ₹1,500 crore QIP (FY26) are parked in mutual funds pending deployment.
Krishna Institute of Medical Sciences (KIMS) reported a steep 47.2 per cent year-on-year fall in consolidated net profit for the first quarter of FY27 (ended 30 June 2026), even as the hospital chain delivered robust double-digit growth in revenue and operating profit, driven by network expansion and rising patient volumes.
Profit and Margin Pressure
KIMS posted a consolidated net profit of ₹41.5 crore in Q1 FY27, a sharp decline from ₹78.6 crore in the same quarter a year ago, according to its stock exchange filing. The fall in profitability came even as the business scaled significantly, pointing to elevated costs associated with rapid expansion.
The EBITDA margin narrowed to 18.9 per cent from 22.1 per cent in Q1 FY26, reflecting the drag from newly commissioned hospitals that typically operate at lower utilisation rates in their early phases.
Revenue and Operating Performance
Revenue from operations climbed 35.3 per cent year-on-year to ₹1,179.5 crore, up from ₹871.6 crore a year earlier, underpinned by higher outpatient and inpatient volumes across its network. EBITDA rose 16 per cent year-on-year to ₹223.4 crore, a solid operational showing even as margins compressed.
Network Expansion and Bed Capacity
KIMS continued to scale its healthcare footprint aggressively during the quarter. Total bed capacity stood at 7,459 as of 30 June 2026, up from 6,464 beds at the end of March 2026 and 5,499 beds a year earlier — a near 36 per cent increase over twelve months.
Chairman and Managing Director B. Bhaskara Rao said the company began FY27 on a strong note with the launch of a new hospital in Palakkad, Kerala. He added that newer hospitals have continued to perform well, with some facilities successfully carrying out complex procedures including lung transplants.
Capital Allocation and QIP Proceeds
On the capital front, KIMS said it has deployed a portion of the ₹1,500 crore raised through a qualified institutional placement (QIP) completed in FY26. The remaining proceeds have been temporarily parked in mutual funds and a monitoring account, pending deployment into further expansion.
Market Reaction
Shares of Krishna Institute of Medical Sciences closed 2.65 per cent higher at ₹826 on the National Stock Exchange (NSE) on Monday, ahead of the quarterly results announcement — suggesting the market had already priced in some optimism around the company's growth trajectory.
With bed capacity expanding at pace and newer units gradually maturing, the pressure on margins is expected to ease as utilisation rates improve in coming quarters.
Point of View
And KIMS is clearly in an investment phase, not a harvest phase. The margin compression from 22.1% to 18.9% EBITDA is manageable if ramp-up timelines hold, but the ₹1,500 crore QIP overhang means investors will be watching deployment pace closely. The stock's 2.65% pre-result gain suggests the market is broadly comfortable with the growth-over-profit trade-off — for now. The risk is if newer hospitals, including Palakkad, take longer than expected to reach viable utilisation, extending the margin drag into FY28.
NationPress
3 Aug 2026
Frequently Asked Questions
Why did KIMS net profit fall so sharply in Q1 FY27?
KIMS net profit fell 47.2 per cent to ₹41.5 crore in Q1 FY27, down from ₹78.6 crore a year ago, primarily due to costs associated with rapid network expansion. New hospitals typically operate at lower utilisation and higher fixed costs in early phases, compressing overall profitability even as revenue grows.
How did KIMS revenue perform in Q1 FY27?
Revenue from operations grew 35.3 per cent year-on-year to ₹1,179.5 crore in Q1 FY27, up from ₹871.6 crore in Q1 FY26. The growth was driven by higher outpatient and inpatient volumes and the addition of new hospitals to its network.
What happened to KIMS EBITDA margin in Q1 FY27?
KIMS EBITDA margin narrowed to 18.9 per cent in Q1 FY27, down from 22.1 per cent in the same quarter last year. EBITDA itself rose 16 per cent to ₹223.4 crore, but the margin decline reflects the cost burden of new hospital launches.
How much has KIMS expanded its hospital network?
KIMS bed capacity grew to 7,459 as of 30 June 2026, up from 5,499 beds a year earlier — a near 36 per cent increase in twelve months. A new hospital was also launched in Palakkad, Kerala, at the start of FY27.
What is KIMS doing with the ₹1,500 crore raised through its QIP?
KIMS raised ₹1,500 crore through a qualified institutional placement in FY26. A portion has been deployed into expansion, while the remaining proceeds are temporarily invested in mutual funds and held in a monitoring account pending further utilisation.
